AvalehtAPN • JSE
add
Aspen Pharmacare Holdings Ltd
Viimane sulgemishind
10 629,00 ZAC
Tänane vahemik
10 339,00 ZAC - 10 635,00 ZAC
Aasta vahemik
9315,00 ZAC - 20 000,00 ZAC
Turuväärtus
46,21 mld ZAR
Keskmine maht
4,01 mln
P/E suhe
-
Dividendimäär
2,04%
Põhibörs
JSE
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (ZAR) | juuni 2025info | Y/Y muutus |
|---|---|---|
Käive | 10,70 mld | −9,17% |
Põhitegevusega seonduv kulu | 5,57 mld | 136,29% |
Puhastulu | −1,74 mld | −266,08% |
Puhaskasumimarginaal | −16,22 | −282,86% |
Puhaskasum aktsia kohta | — | — |
EBITDA | −704,50 mln | −124,06% |
Tõhus maksumäär | −4,93% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (ZAR) | juuni 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 6,41 mld | −48,05% |
Kogu vara | 135,89 mld | −2,34% |
Kõik kohustused | 51,00 mld | −6,07% |
Kogu omakapital | 84,89 mld | — |
Emiteeritud aktsiate arv | 443,90 mln | — |
Hinna ja väärtuse suhe P/B | 0,56 | — |
Varade tasuvus | −2,26% | — |
Kapitali tasuvus | −2,54% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (ZAR) | juuni 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | −1,74 mld | −266,08% |
Põhitegevuse rahakäive | 1,68 mld | −10,96% |
Investeeringute raha | −1,21 mld | 26,47% |
Finantseerimise raha | −560,50 mln | −296,11% |
Raha ja raha ekvivalentide muutus | −197,50 mln | 1,25% |
Tasuta rahavoog | −1,72 mld | −428,35% |
Teave
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
Tegevjuht
Asutatud
1850
Veebisait
Töötajate arv
9 109
